580 results found
Venable LLP | USA | 5 Jun 2023
Supreme Court affirms lack of enablement in Amgen v Sanofi antibody patent dispute
The Supreme Court recently issued a unanimous decision in Amgen v Sanofi, construing the statutory enablement requirement. The Court reaffirmed Congress's judgment that "if an inventor claims a lot, but enables only a little, the public does not receive its benefit of the bargain". The Court's opinion elsewhere made clear, however, that this was not a bright-line rule. Accordingly, enablement......
Rothwell, Figg, Ernst & Manbeck, PC | USA | 17 Apr 2019
Eli Lilly Files PGR Petition against Genentech’s IL-17A/F Heterodimer Patent
On April 2, 2019, Eli Lilly and Company (“Lilly”) filed a Petition for Post-Grant Review (“PGR”) of Genentech’s U.S. Patent 10,011,654 (“the ’654…
Rothwell, Figg, Ernst & Manbeck, PC | USA | 18 Mar 2019
Jury Finds Amgen Antibody Patents Not Invalid
Over four years ago, in October 2014, Amgen initiated a patent infringement suit against Sanofi and Regeneron regarding biologics for treatment of…
Rothwell, Figg, Ernst & Manbeck, PC | USA | 24 Feb 2019
Sandoz Files Declaratory Judgment of Non-Infringement For Filgrastim-Related Patent
According to Sandoz, the ʼ997 patent is in the same patent family as U.S. Patent No. 8,940,878 (“the ʼ878 patent”), which Amgen asserted against…
Proskauer Rose LLP | USA | 10 Jan 2019
ERISA Newsletter
As we closed the door on 2018, we were met by two surprising decisions—one from a panel of the Second Circuit addressing employer…
Dinsmore & Shohl LLP | USA | 8 Jan 2019
Federal District Court Rules HHS Cuts to 340B Reimbursement 'Exceeded' Authority
In a recent opinion out of the U.S. District Court for the District of Columbia, U.S. District Court Judge Rudolph Contreras held that the U.S…
Mintz | USA | 2 Jan 2019
340B, When a Price Adjustment is Not Really an Adjustment, and the Implications for CMS Efforts to Attack Drug Prices
The Federal Courts gave the America Hospital Association and 340B covered entities a late Christmas present and in doing so may have dealt a blow to…
Bereskin & Parr LLP | USA | 29 Nov 2018
Amgen v Sanofi - Neutralizing Antibody to Antigen claims
Recent case law in the United States has changed the landscape for patenting antibodies. In Amgen v Sanofi, 872 F.3d 1367, the Federal Circuit ruled…
Smart & Biggar | Canada | 1 Nov 2018
Amgen not precluded from asserting patent under current PMNOC Regulations even though unsuccessful under old PMNOC Regulations
The Federal Court of Canada has refused Pfizer’s motion to dismiss an action under the Patented Medicines (Notice of Compliance) Regulations (PMNOC…
Smart & Biggar | Canada | 24 Sep 2018
Federal Court dismisses first motion for early dismissal under amended PMNOC Regulations
The Federal Court recently dismissed the first motion for summary dismissal brought under Section 6.08 of the amended Patented Medicines (Notice of Compliance) Regulations. The underlying action for infringement concerned Amgen Canada's regulatory submission for approval of its biosimilar of Hoffmann-La Roche's Herceptin. Amgen sought to dismiss the action regarding two of the four asserted......
